— Research monograph
BPC-157 + TB-500 (Wolverine)
A co-formulation of two repair-pathway peptides in a single lyophilized vial.
Updated
- Class
- Pentadecapeptide (BPC-157) + Thymosin Beta-4 fragment (TB-500) co-formulation
- Half-life (research)
- BPC-157: ~4 hr (preclinical, rat). TB-500: not well-characterized in the public literature.
- Origin
- BPC-157 was first characterized at the University of Zagreb by the Sikiric laboratory in the early 1990s as a stable fragment of body protection compound, a polypeptide identified in gastric juice. Thymosin Beta-4 (the parent peptide of TB-500) was originally isolated from bovine thymus by Allan Goldstein in 1981.
- Solubility
- Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures.
What is BPC-157 + TB-500 (Wolverine)?
BPC-157 is a synthetic pentadecapeptide consisting of fifteen amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a fragment of body protection compound, a polypeptide originally identified in human gastric juice. It is notable in the peptide literature for unusually high stability in acidic environments — a property that has made it a frequent subject of preclinical investigation.
TB-500 is a synthetic acetylated 17-amino-acid fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide naturally expressed in most mammalian tissues. The fragment corresponds to the active actin-binding region of the parent peptide.
The Wolverine co-formulation places both peptides in a single lyophilized vial at 10 mg each. Researchers requesting this blend most commonly cite combined-pathway repair studies as their rationale for the pairing.
How does BPC-157 + TB-500 (Wolverine) work?
BPC-157 has been investigated in preclinical models for effects on angiogenesis (VEGF/VEGFR2 axis modulation), nitric oxide system regulation, growth hormone receptor expression, and dopaminergic / serotonergic system interactions. TB-500 functions primarily as an actin-sequestering protein involved in cell motility, organogenesis, and the regulation of actin polymerization in research models. Both peptides remain under active investigation; mechanisms described above reflect preclinical findings, not clinical conclusions.
Research applications
- Tissue-repair pathway investigation
- Tendon and ligament healing models
- Vascular angiogenesis research
- GI mucosal integrity studies
- Actin cytoskeleton dynamics
BPC-157 + TB-500 (Wolverine) at Merit
Research review on The Assay, Merit’s editorial publication: BPC-157 vs TB-500: What the Published Research Actually Compares
Research review on The Assay, Merit’s editorial publication: TB-500 vs Thymosin Beta-4: What the Research Covers
Form & storage
BPC-157 + TB-500 (Wolverine) ships as a sealed, lyophilized (freeze-dried) powder. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures. Store sealed, light-protected, and follow your institution’s handling procedures for research materials.
Frequently asked questions
What is BPC-157 + TB-500 (Wolverine)?
BPC-157 is a synthetic pentadecapeptide consisting of fifteen amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a fragment of body protection compound, a polypeptide originally identified in human gastric juice. It is notable in the peptide literature for unusually high stability in acidic environments — a property that has made it a frequent subject of preclinical investigation. Merit supplies it as a lyophilized research compound for research use only, not for human or veterinary use.
How does BPC-157 + TB-500 (Wolverine) work?
BPC-157 has been investigated in preclinical models for effects on angiogenesis (VEGF/VEGFR2 axis modulation), nitric oxide system regulation, growth hormone receptor expression, and dopaminergic / serotonergic system interactions. TB-500 functions primarily as an actin-sequestering protein involved in cell motility, organogenesis, and the regulation of actin polymerization in research models. Both peptides remain under active investigation; mechanisms described above reflect preclinical findings, not clinical conclusions. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.
What is the half-life of BPC-157 + TB-500 (Wolverine)?
BPC-157: ~4 hr (preclinical, rat). TB-500: not well-characterized in the public literature. Values reflect preclinical or research-context reports, not clinical pharmacokinetics.
Is Merit BPC-157 + TB-500 (Wolverine) for human use?
No. It is sold strictly for research use only: not for human or veterinary use, and not for diagnostic or therapeutic use.
Is BPC-157 + TB-500 (Wolverine) FDA-approved?
Neither BPC-157 nor TB-500 is approved by the FDA for any use, and no FDA-approved product combines them. Supplied for research use only. Both components are named on the WADA 2026 Prohibited List: BPC-157 under S0 and TB-500 under S2.
How is each batch of BPC-157 + TB-500 (Wolverine) tested?
Every Merit batch is tested by an independent laboratory for identity and HPLC purity before it is listed, and Merit identifies batches by date rather than by lot number. Current certificates: Wolverine (BPC-157 + TB-500) 20 mg, July 2026 batch, 99.51% purity (meritsciences.com/coa/COA-2026-Z6RSEN).
Regulatory status checked October 22, 2026 against: FDA advisory committee meeting, committee vote report (Healio), FDA Category 2 list, WADA Prohibited List.
References
- Stable Gastric Pentadecapeptide BPC 157-NO-system Relation. Sikiric P, Seiwerth S, Rucman R, et al.. Current Pharmaceutical Design, 2014 · doi:10.2174/13816128113190990411
- Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Sikiric P, Rucman R, Turkovic B, et al.. Current Neuropharmacology, 2016 · PMID 27138887
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Expert Opinion on Biological Therapy, 2012 · PMID 22074294
For research use only. Not for human or veterinary use. Reference information summarized from published literature, not medical advice.